Overview
Stimwave develops wireless, minimally invasive neurostimulation devices for chronic pain management, featuring the world's smallest spinal cord stimulator powered by external radio frequency energy.
Stimwave Technologies is a neurotechnology company headquartered in Pompano Beach, Florida, specializing in wireless neurostimulation devices for chronic pain management. The company has developed the world's smallest spinal cord stimulator, which utilizes external radio frequency energy to deliver therapy without requiring implanted batteries or leads. This innovative approach enables minimally invasive procedures that reduce surgical complexity and patient recovery time compared to traditional neuromodulation systems.
Stimwave has established itself as a significant player in the neuromodulation market through sustained investment and development, culminating in a Series C funding round of $85 million. This substantial capital infusion demonstrates strong investor confidence in the company's technology platform and commercial potential. The funding supports both clinical validation and market expansion, positioning Stimwave to compete with established players in the chronic pain management space while maintaining its technological edge in miniaturization and wireless innovation.
The company represents an important advancement in neurotech by addressing key limitations of conventional spinal cord stimulation systems, including the need for battery replacement surgeries and lead-related complications. By eliminating implanted power sources through RF-powered technology, Stimwave reduces long-term patient burden and opens chronic pain treatment options to patients who may be poor candidates for traditional devices. Their work exemplifies how miniaturization and wireless power transfer are transforming neuromodulation, setting new standards for patient safety, comfort, and clinical outcomes in chronic pain management.
More in Neuromodulation
Latest industry news
Synchron Closes $275M Series D to Accelerate Stentrode BCI Commercialization
2026-06-15 · Funding
MIT Researchers Demonstrate Real-Time Emotion Decoding via Non-Invasive EEG with 94% Accuracy
2026-06-13 · Research
Synchron Launches Stentrode Home Edition, Expanding BCI Access Beyond Clinical Settings
2026-06-11 · Product
Synchron Reaches 100-Patient Milestone as Stentrode BCI Moves Toward Pivotal Trial
2026-06-09 · Industry
Company details
Category
⚡ Neuromodulation
Location
Pompano Beach, FL, USA
Funding
Series C · $85M
Website
www.stimwave.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →